The research focused on one of the most medically vulnerable populations in oncology: patients with blood cancers undergoing allogeneic hematopoietic cell transplantation. In this intensive procedure, patients receive high-dose chemotherapy, sometimes combined with radiation, to destroy their immune systems before donor stem cells are introduced to rebuild them. These individuals spend weeks in the hospital and are routinely given antibiotics to prevent and treat infections during the period when their defenses are essentially wiped out. Eighty percent of the patients in the study received at least one broad-spectrum antibiotic, the class of drugs that exerts the strongest impact on the microbiome because it targets many types of bacteria at once, obliterating beneficial organisms along with dangerous ones.

Antibiotics are, of course, lifesaving tools, but their broad activity comes at a cost. By indiscriminately killing bacteria, they can hollow out the gut’s ecological diversity, creating space for opportunistic pathogens to flourish. Microbiome diversity is widely regarded as a key indicator of gut health, and its loss has previously been linked with poorer clinical outcomes in patients with cancer. Preserving that diversity, the new study suggests, may be within patients’ control through something as ordinary as their meal choices.

What sets this investigation apart from most nutrition research is the extraordinary granularity of its dietary data. Over five years, the research team tracked 9,419 meals eaten by 173 hospitalized patients. Every time a patient ordered a meal from the hospital kitchen, the tray arrived with a questionnaire asking them to record how much of each item they ate and drank. By combining these real-time records with the kitchen’s nutritional information, the scientists catalogued more than 40,000 individual food items. For each patient, the team followed between eight and 128 meals across a window stretching from 12 days before transplantation to 49 days after. In parallel, they profiled microbiome diversity in more than 1,000 stool samples from 158 patients.

Marcel van den Brink, M.D., Ph.D., co-senior author of the study and president of City of Hope Los Angeles and City of Hope chief physician executive, emphasized how unusual this dataset is. Unlike past nutrition studies that depend on patients’ recollections of what they ate or on other imprecise surveys, his team worked with meticulous dietary records collected in real time, a level of detail that allowed them to detect patterns that would otherwise be impossible to see. Van den Brink, a globally recognized leader in microbiome research, cell transplantation and cancer immunotherapy, collaborated with Jonathan Peled, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center and Jonas Schluter, Ph.D., of NYU’s Grossman School of Medicine.

Armed with this data, the researchers deployed a battery of advanced statistical models to search for dietary patterns associated with injury to the gut microbiome. The signal that emerged was strikingly consistent. No matter how the team analyzed the data, the same result kept appearing: patients who consumed more sweets while taking antibiotics were more likely to experience a loss of microbiome diversity as aggressive microbes crowded out other strains of bacteria. One organism in particular stood out, Enterococcus, a bacterium whose domination of the gut is associated with a higher risk of bloodstream infections, graft-versus-host disease and other life-threatening complications in transplant patients.

The magnitude of the effect was substantial. The combination of high-sugar foods and broad-spectrum antibiotics appeared to multiply the damage to the microbiome, producing a 24 percent drop in bacterial diversity for every 100-gram increase in sweets consumed, an amount of sugar roughly equivalent to a large milkshake. In other words, the dietary factor did not merely add to antibiotic-induced injury; it appeared to interact with it, deepening the ecological collapse that broad-spectrum drugs alone can trigger.

To test whether the association reflected a genuine biological mechanism rather than a statistical coincidence, the researchers turned to animal models. They gave broad-spectrum antibiotics to healthy mice and fed the animals a variety of diets. Mice eating a high-sucrose diet rapidly developed an overgrowth of Enterococcus in their guts, mirroring the pattern seen in the hospitalized patients. Critically, mice that ate the high-sugar diet without receiving antibiotics maintained normal bacterial diversity, indicating that sugar alone was not the culprit; rather, it was the combination of sugar and antibiotics that proved destructive. Van den Brink noted that the convergence of animal studies with the patient data provides a compelling rationale for future clinical trials to evaluate whether reducing sugar intake during antibiotic use would protect the microbiome.

The implications extend well beyond the transplant ward. The microbiome is increasingly recognized as an important factor in cancer care, influencing how patients respond to therapy and how they recover from it, and the better clinicians understand what supports or disrupts it, the more opportunities they have to reduce treatment side effects. For hospitalized cancer patients, diet represents one of the most practical levers hospitals can pull to support recovery. Van den Brink pointed out an uncomfortable irony in current clinical practice: many of the foods and drinks that hospitals encourage patients to consume, including nutritional shakes, smoothies and sports drinks, are high in sugar, something he said will need to be re-evaluated when prescribing antibiotics.

The study also reframes the concept of antibiotic stewardship. Traditionally, stewardship has focused on limiting antibiotic use to prevent the emergence of resistance, but the new findings suggest it should also encompass how different antibiotics affect the microbiome, since some disrupt beneficial gut bacteria far more than others. Van den Brink encourages patients to ask their healthcare teams to ensure that antibiotics are thoughtfully chosen from equally effective treatment options for controlling infections. As for whether people on antibiotics should simply cut out sugar, he counsels a measured approach. It is premature, he said, to recommend that everyone taking antibiotics avoid sugar, but he also observed that there is no strong evidence that probiotics help preserve or restore microbiome diversity, even though many people take them anyway. Limiting sugar, by contrast, carries no known harm and is an easy thing to try. The work was supported by the National Cancer Institute, the National Heart, Lung and Blood Institute, and the Susan and Peter Solomon Microbiome, Nutrition and Cancer Program at Memorial Sloan Kettering Cancer Center, and it reinforces a growing movement in medicine to treat food not merely as fuel but as an active component of therapeutic care.

Subject of Research: The interaction between dietary sugar and antibiotics in disrupting gut microbiome diversity in cancer patients undergoing stem cell transplantation

Article Title: Study suggests skipping sweets during antibiotic treatment may help protect the gut microbiome

Article References: Study suggests skipping sweets during antibiotic treatment may help protect the gut microbiome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gut microbiome, antibiotics, sugar, stem cell transplant, microbiome diversity, Enterococcus, cancer care, nutrition, food as medicine, City of Hope, Nature, antibiotic stewardship

The research, led by Ethan Gough and Soumya Basu of the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, together with senior author Subhra Chakraborty and colleagues, drew on stool samples and immune measurements from 27 adult volunteers who participated in a controlled clinical trial. Each volunteer received two doses of ACE527, a live attenuated oral ETEC vaccine candidate, and was subsequently challenged with the virulent ETEC strain H10407, a well-characterized isolate that has long served as a benchmark strain in human challenge studies of enteric vaccines. The trial was registered under ClinicalTrials.gov identifier NCT01060748, and the microbiome analysis was approved by the Johns Hopkins University Institutional Review Board under protocol IRB 20100221.

To characterize the bacterial communities living in the participants’ intestines, the team performed 16S ribosomal RNA sequencing on stool samples collected during the trial. This technique amplifies and sequences a molecular marker present in all bacteria, allowing researchers to identify which microbial taxa are present and in what relative abundances, without needing to culture the organisms in the laboratory. From these data the investigators computed two standard measures of community structure: alpha diversity, which captures how many species are present and how evenly distributed they are within a single sample, and beta diversity, which measures how similar or different microbial communities are between individuals or across time points.

The immune outcomes of interest were drawn from enzyme-linked immunosorbent assay measurements of antibody responses directed against two key ETEC antigens: the B subunit of heat-labile toxin, known as LTB, and colonization factor antigen I, or CFA/I, a surface structure the bacteria use to adhere to the intestinal lining. Antibodies were quantified both in serum, reflecting systemic immunity, and in the antibody-in-lymphocyte-supernatant assay, or ALS, which captures antibodies secreted by circulating plasmablasts and serves as a surrogate for mucosal immune activation in the gut. Both IgG and IgA classes were measured, with IgA of particular interest because it is the dominant antibody isotype at mucosal surfaces and is widely regarded as a correlate of protection against intestinal pathogens.

The statistical analysis went well beyond simple comparisons. The team used regression models to link individual bacterial taxa to immune readouts, applied the Microbiome Regression-Based Kernel Association Test, known as MiRKAT, to test whether overall community composition predicted immune responses, and employed a relaxed least absolute shrinkage and selection operator, or LASSO, approach to identify parsimonious sets of taxa associated with protection. Protection itself was assessed clinically, based on whether volunteers developed severe diarrhea and on whether ETEC could be detected as colonizing the gut after the challenge with H10407.

One of the clearest signals emerged from the alpha diversity analysis. Volunteers with higher inverse-Simpson diversity, a metric that increases both with the number of species present and with their evenness, tended to mount weaker ALS IgA responses against both LTB and CFA/I. In other words, a more diverse gut community was associated with a blunted mucosal antibody response to the vaccine. This finding is intriguing because it runs counter to the common assumption that greater microbial diversity is inherently beneficial; in the specific context of oral live attenuated vaccine immunogenicity, a densely populated and diverse intestinal ecosystem may compete with the vaccine strain or modulate innate immune signaling in ways that dampen the antigen-specific response.

Beta diversity told a different story. The overall composition of the gut community, considered as a whole, correlated with increased serum anti-CFA/I IgA, suggesting that the identity of the microbes present, rather than simply their number, shapes the systemic arm of the antibody response. At the level of individual taxa, the vaccination series was associated with a measurable increase, on the order of 25 to 30 percent, in the relative abundance of several groups, including the Eubacterium brachy group, members of Family XIII AD3011, and Actinomyces. Whether these shifts represent a direct effect of vaccine colonization on the ecosystem or an indirect consequence of the immune activation that vaccination triggers remains an open question, but the consistency of the direction of change across participants suggests a reproducible vaccine-microbiome interaction.

Perhaps the most consequential findings concerned specific bacterial families whose abundance tracked with protection. Members of Anaerovoraceae, Peptostreptococcaceae, Oscillospiraceae, and Veillonellaceae were associated with enhanced immune responses and, importantly, with protection against severe diarrhea and against ETEC colonization following the challenge. In contrast, several other groups, including Ruminococcaceae, Sutterellaceae, Coriobacteria, Clostridia, and Actinobacteria, showed antagonistic associations, being linked in the opposite direction with immune outcomes or protection. These antagonistic taxa are not necessarily harmful in their own right; the associations are statistical relationships that require mechanistic follow-up. Nonetheless, the pattern suggests that the interplay between a person’s resident microbiota and an oral vaccine is not uniform across the microbial community but instead involves specific lineages that either support or hinder the generation of protective immunity.

The implications for vaccine development are considerable. Oral live attenuated vaccines must survive passage through the stomach, establish limited replication in the intestine, and present their antigens to the gut-associated lymphoid tissue, and every one of those steps occurs in the context of a complex microbial ecosystem that can facilitate or obstruct them. If the microbiome modulates take of the vaccine strain, the magnitude of mucosal IgA responses, or the likelihood of sterilizing protection after exposure to wild-type bacteria, then microbiome status may help explain a long-standing puzzle in ETEC vaccine research: why candidate vaccines that perform reasonably well in controlled human challenge studies among adults in industrialized settings often show weaker immunogenicity and efficacy when tested in infants and young children in endemic countries, whose gut communities differ markedly from those of the trial volunteers in Baltimore.

The authors emphasize that the study, funded by the National Institute of Allergy and Infectious Diseases through grants R01AI153399 and R56AI168316 and additionally supported by the PATH agreement GAT.1371-05689-CTA, is an early step in a longer research program. With 27 participants, the analysis is necessarily exploratory, and associations identified through sequencing and regression modeling will need to be validated in larger and more diverse cohorts, ideally including populations in ETEC-endemic regions where the public health burden is greatest. Still, the work offers a concrete roadmap: specific taxonomic markers, measurable by inexpensive 16S sequencing, could eventually help researchers stratify volunteers in vaccine trials, stratify risk in endemic populations, or even guide the rational use of microbiome-directed adjuncts such as targeted prebiotics to maximize the protective potential of future ETEC vaccines. As enteric vaccine science matures, it appears increasingly clear that the answer to whether a vaccine works may lie not only in the vaccine itself but in the trillions of microbes with which it shares the intestine.

Subject of Research: How gut microbiota composition influences immune responses and protection following oral ETEC vaccination and challenge

Article Title: Influence of gut microbiota on immune responses and protection in volunteers receiving the live attenuated oral ETEC vaccine ACE527 followed by virulent ETEC H10407 challenge

Article References: Gough, E., Basu, S., Brubaker, J., DeNeraing, B., Sack, D., Bourgeois, A. L., Walker, R., Harro, C. D., & Chakraborty, S. (2026). Influence of gut microbiota on immune responses and protection in volunteers receiving the live attenuated oral ETEC vaccine ACE527 followed by virulent ETEC H10407 challenge. Gut Pathogens. https://doi.org/10.1186/s13099-026-00878-6

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00878-6

Keywords: ETEC, gut microbiota, ACE527 vaccine, H10407 challenge, IgA response, mucosal immunity, 16S rRNA sequencing, diarrhea, vaccine immunogenicity, microbiome diversity, Influence, microbiota

The starting point for the framework is a deceptively simple observation: the gut microbiome of social bees is remarkably small and specific compared with that of mammals. Honey bees and bumble bees harbour a core set of bacterial symbionts that have coevolved with their hosts and are transmitted socially, passing between nestmates through shared food, faecal contact and the communal environment of the hive. These microbes contribute to nutrition by aiding the digestion of pollen, to detoxification of harmful compounds, to immune priming against pathogens, and even to behaviour, with measurable consequences for colony performance and resilience. Yet despite the field’s rapid growth, most studies continue to analyse host genetics and environmental exposures separately, and many rely on simple correlations between the abundance of particular microbes and health traits such as parasite resistance or longevity.

That reliance on correlation is where the trouble begins, the authors argue. When researchers observe that bees with a certain microbiome profile are healthier, it is difficult to know what is driving what. The microbiome differences may reflect underlying host genetics, they may be a consequence of environmental exposure, or they may genuinely contribute mechanistically to the health outcome. Disentangling these possibilities is one of the central challenges in bee microbiome research, and the GEM–P framework is designed precisely to make this disentangling more systematic. It treats the genome, the exposome and the gut microbiome as interacting components that jointly shape phenotypes, while phenotypes themselves feed back to modify subsequent exposures and microbiome states, creating a dynamic, looping system rather than a one-directional chain of cause and effect.

Each component of the framework carries specific technical meaning. The genome encompasses host genetic variation, which can filter which microbes are able to colonise the gut, a process the authors describe as genetic filtering. The exposome captures the totality of lifetime exposures, including diet, pesticides, pathogens, temperature and landscape characteristics, all of which can reshape the microbial community or act directly on bee physiology. The microbiome refers to the gut symbionts themselves and their assembly dynamics and functions. The phenome covers the full suite of observable traits, from individual characteristics such as immune gene expression and nutrient processing to colony-level outcomes such as brood production, overwintering success and disease burden. Crucially, the framework operates at both scales simultaneously, recognising that colony phenotypes emerge from the actions and interactions of thousands of individuals.

Perhaps the most intellectually important contribution of the review is its treatment of context dependence. The authors highlight three major sources of it: scale, timing and social transmission. Similar microbiome shifts can be associated with different trait outcomes depending on the life stage and task of the bee, since nurse bees and foragers, or larvae and adults, have distinct physiologies and diets. Exposure history matters too, because a bee that has previously encountered a pesticide may respond differently to a microbial change than a naive individual. And the colony’s transmission structure, the way microbes are shared among nestmates, means that an individual’s microbiome is inseparable from its social environment. A microbial pattern that signals dysbiosis in one context may be an adaptive response in another, which helps explain why apparently contradictory findings recur across the literature.

To illustrate the framework’s utility, the authors use GEM–P to map existing evidence on genetic filtering, exposomal drivers, microbiome assembly and function, and phenotypic outcomes. This mapping exercise reveals where the evidence is strong and where it remains thin. For example, host genetics clearly constrain which symbionts can establish in the bee gut, and dietary exposures demonstrably alter the relative abundance of core taxa, but the mechanistic links connecting specific microbial functions to specific colony outcomes are far less well established. By laying the components out in a single organisational scheme, researchers can identify which pathway connecting genome, exposome, microbiome and phenotype is being invoked in any given hypothesis, and design sampling strategies that test that pathway specifically rather than relying on broad correlational surveys.

Importantly, the authors stress that generating pathway-specific hypotheses does not require comprehensive multi-omics approaches, which remain expensive and technically demanding for many laboratories. Instead, GEM–P supports relatively simple, targeted study designs. Sampling across life stages and castes, recording exposure histories, accounting for colony-level transmission, and measuring phenotypes at matched individual and colony scales can all help distinguish among alternative biological explanations for a microbiome–phenotype association without sequencing everything. The framework thus serves as a guide for experimental economy, pointing researchers toward the comparisons that are most informative for ruling out competing interpretations, such as whether a microbiome shift precedes or follows a change in host state, or whether it is shared across related bees in a way consistent with genetic filtering.

The implications extend beyond basic science into the practical world of beekeeping and pollination services. Social bees underpin agriculture through their pollination of crops and wild plants, and colony losses have economic and ecological consequences that are now felt worldwide. If microbiome-based interventions, such as probiotic supplements or management practices that support beneficial symbionts, are to be developed responsibly, they must rest on an understanding of when microbial change actually causes improvements in health and when it is merely a bystander. GEM–P offers a way to formulate those questions rigorously, linking interventions to specific points in the genome–exposome–microbiome–phenome network and specifying the outcomes and contexts in which effects should be expected. The work also contributes to the objectives of the BeeSustain project, an initiative on integrative modelling for enhanced beekeeping carrying capacity funded through Xjenza Malta’s Research Excellence Programme.

The review, published open access on 3 September 2026, arrives at a moment when the bee microbiome literature has grown rapidly but interpretively fragmented, with different subfields emphasising different components of the system and rarely integrating them. By providing a shared vocabulary and a common structural map, the authors hope the framework will help researchers interpret microbiome–phenotype associations across contexts, generate hypotheses that are explicitly pathway-specific, and design studies whose results genuinely advance mechanistic understanding. For a field in which correlation has often been mistaken for causation, and in which the same microbial signal can mean different things in a larva, a nurse bee or an overwintering colony, that kind of conceptual discipline may prove as valuable as any single experiment. The GEM–P framework does not claim to answer how social bee health is determined, but it tells the research community, with unusual clarity, exactly which questions to ask next.

Subject of Research: An integrative framework linking genome, exposome, gut microbiome and phenome in social bees

Article Title: The Genome Exposome Microbiome–Phenome (GEM–P): a conceptual framework for social bees

Article References: Cutajar, S., Alberoni, D., Di Gioia, D., & Mifsud, D. (2026). The Genome Exposome Microbiome–Phenome (GEM–P): a conceptual framework for social bees. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14016-4

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14016-4

Keywords: social bees, gut microbiome, exposome, genome, phenome, GEM–P framework, colony health, microbial transmission, symbiosis, bee resilience, host genetics, context dependence